Afuco™ Anti-Human EMP2 ADCC Therapeutic Antibody (PG-101), ADCC Enhanced
Anti-EMP2 ADCC Enhanced Antibody (PG-101) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a novel IgG1 monoclonal antibody to EMP2, PG-101 treatment in the primary tumor is sufficient to reduce secondary tumor formation in triple negative breast cancer cells on the order of 1:20, 000 compared to the control treated mice. PG-101 in combination with docetaxel can cure up to 80% of animals treated. This effect is lasting as these mice have shown no rebound in tumor load more than 2 months following the last treatment. Collectively, these results show that PG-101 therapy has the potential to revolutionize the outcomes for women with breast cancer.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-219CL |
| Pricing | Inquiry |
| Host | Human |
| Target | EMP2 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at –20 or -70°C upon receipt. Divide antibody into aliquots prior usage and avoid multiple freeze-thaw cycles. |